PBM (Psyence Biomedical) Ending Cash Position: $0.30 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBM Psyence Biomedical Ltd PBM
14 GF Score
Price $5.40
! 4 Warning Signs
View Full Analysis

What is Psyence Biomedical Ending Cash Position?

Psyence Biomedical PBM +9.64% 14 Ending Cash Position is $0.30 Mil as of Mar. 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Psyence Biomedical's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.30 Mil.

Psyence Biomedical's quarterly Ending Cash Position increased from Mar. 2025 ($4.20 Mil) to Sep. 2025 ($7.15 Mil) but then declined from Sep. 2025 ($7.15 Mil) to Mar. 2026 ($0.30 Mil).

Psyence Biomedical's annual Ending Cash Position increased from Mar. 2024 ($0.73 Mil) to Mar. 2025 ($6.14 Mil) and increased from Mar. 2025 ($6.14 Mil) to Mar. 2026 ($7.45 Mil).

Psyence Biomedical Ending Cash Position Related Terms

Psyence Biomedical Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Psyence Biomedical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psyence Biomedical Ending Cash Position Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial 1.76 1.33 0.73 6.14 7.45

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 1.93 4.20 7.15 0.30
PBM
14GF Score
Psyence Biomedical Ltd PBM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Psyence Biomedical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Psyence Biomedical's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=6.135+1.31
=7.45

Psyence Biomedical's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.5511151231258E-17+0.295
=0.30

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.30 Mil mean?
Psyence Biomedical (PBM) has a Ending Cash Position of $0.30 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Psyence Biomedical and its competitors.
Is Psyence Biomedical's Ending Cash Position too high?
Psyence Biomedical's current Ending Cash Position is $0.30 Mil. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's Ending Cash Position compare to NRSN and PLUR?
Psyence Biomedical's Ending Cash Position of $0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Psyence Biomedical and its competitors. Psyence Biomedical's current Ending Cash Position is $0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current Ending Cash Position of $0.30 Mil. The current Ending Cash Position is $0.30 Mil. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current Ending Cash Position is $0.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Psyence Biomedical Business Description

Address 121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score

Get the complete analysis for PBM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.40
Price